A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a ...

Topline data were announced from a phase 3 trial evaluating varegacestat in patients with progressing desmoid tumors.

Anova Enterprises has launched the AnovaOS software-as-a-service (SaaS) platform, a new AI-based patient matching solution for clinical trials. The solution is part of a global just-in-time research ...

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced the U.S. launch of the next generation LifeVest® wearable cardioverter defibrillator (WCD).

Negative symptoms of schizophrenia affect motivation, emotion, and daily life. Learn the signs, why they’re often missed, and ...

The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity ...

Joel S. Schuman, MD, FACS, highlights home tonometry, virtual visual fields, and portable OCT devices as promising tools, ...

Astellas and Pfizer announced that neoadjuvant plus adjuvant enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) ...

AstraZeneca’s LATIFY phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet its primary endpoint of overall survival in ...

In this study, researchers sought to determine the impact of the FDA’s Accelerated Approval pathway among patients with solid tumors.

In 2025, cardiology delved deeper into sex-specific risk factors and how to leverage them in prevention, Stacey Rosen says.